Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Molecular Features of HHV8 Monoclonal Microlymphoma Associated with Kaposi Sarcoma and Multicentric Castleman Disease in an HIV-Negative Patient.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
    • نبذة مختصرة :
      Human herpesvirus 8 (HHV8)-associated diseases include Kaposi sarcoma (KS), multicentric Castleman disease (MCD), germinotropic lymphoproliferative disorder (GLPD), Kaposi sarcoma inflammatory cytokine syndrome (KICS), HHV8-positive diffuse large B-cell lymphoma (HHV8+ DLBCL), primary effusion lymphoma (PEL), and extra-cavitary PEL (ECPEL). We report the case of a human immunodeficiency virus (HIV)-negative male treated for cutaneous KS, who developed generalized lymphadenopathy, hepatosplenomegaly, pleural and abdominal effusions, renal insufficiency, and pancytopenia. The excised lymph node showed features of concomitant involvement by micro-KS and MCD, with aggregates of HHV8+, Epstein Barr virus (EBV)-negative, IgM+, and lambda+ plasmablasts reminiscent of microlymphoma. Molecular investigations revealed a somatically hypermutated (SHM) monoclonal rearrangement of the immunoglobulin heavy chain (IGH), accounting for 4% of the B-cell population of the lymph node. Mutational analyses identified a pathogenic variant of KMT2D and variants of unknown significance in KMT2D , FOXO1 , ARID1A , and KMT2A . The patient died shortly after surgery. The histological features (HHV8+, EBV-, IgM+, Lambda+, MCD+), integrated with the molecular findings (monoclonal IGH, SHM+, KMT2D mutated), supported the diagnosis of a monoclonal HHV8+ microlymphoma, with features intermediate between an incipient HHV8+ DLBCL and an EBV-negative ECPEL highlighting the challenges in the accurate classification of HHV8-driven lymphoid proliferations.
    • References:
      Am J Surg Pathol. 2008 Jul;32(7):1006-12. (PMID: 18469709)
      Pract Lab Med. 2020 Nov 25;22:e00191. (PMID: 33304977)
      Nature. 2011 Jul 27;476(7360):298-303. (PMID: 21796119)
      Leukemia. 2019 Sep;33(9):2227-2240. (PMID: 31197258)
      Blood. 2022 Sep 15;140(11):1229-1253. (PMID: 35653592)
      Diagnostics (Basel). 2022 Jan 24;12(2):. (PMID: 35204381)
      Am J Dermatopathol. 2020 Jan;42(1):55-60. (PMID: 31361614)
      Mol Clin Oncol. 2019 Feb;10(2):318-320. (PMID: 30680214)
      Histopathology. 2015 Dec;67(6):930-2. (PMID: 25900626)
      BMC Blood Disord. 2003 Dec 11;3(1):3. (PMID: 14670091)
      Clin Infect Dis. 2013 Mar;56(6):833-42. (PMID: 23223599)
      Haematologica. 2009 Aug;94(8):1170-4. (PMID: 19608668)
      Cancer Cytopathol. 2021 Jan;129(1):62-74. (PMID: 32975904)
      Blood. 2022 Feb 17;139(7):1013-1025. (PMID: 34479367)
      Nat Med. 2018 May;24(5):679-690. (PMID: 29713087)
      Am J Transplant. 2017 Nov;17(11):2963-2969. (PMID: 28489271)
      Nat Immunol. 2009 Jun;10(6):647-54. (PMID: 19412180)
      Leukemia. 2022 Jul;36(7):1720-1748. (PMID: 35732829)
      Immunity. 2021 Aug 10;54(8):1807-1824.e14. (PMID: 34380064)
      Am J Surg Pathol. 2006 Jan;30(1):123-7. (PMID: 16330952)
      Blood. 2000 Feb 15;95(4):1406-12. (PMID: 10666218)
      Oncoimmunology. 2021 Jul 20;10(1):1928365. (PMID: 34350060)
      Am J Clin Pathol. 2017 Feb 01;147(2):171-187. (PMID: 28395104)
      Blood. 2003 Sep 1;102(5):1833-41. (PMID: 12714522)
      Blood. 2001 Apr 1;97(7):2130-6. (PMID: 11264181)
      Am J Surg Pathol. 2007 Sep;31(9):1439-45. (PMID: 17721201)
      Clin Infect Dis. 2016 Mar 15;62(6):730-738. (PMID: 26658701)
      PLoS Pathog. 2018 Apr 16;14(4):e1006967. (PMID: 29659614)
      Virchows Arch. 2023 Sep;483(3):299-316. (PMID: 37555981)
      Patholog Res Int. 2010 Dec 30;2011:647518. (PMID: 21253546)
      Blood. 2020 Apr 16;135(16):1353-1364. (PMID: 32106302)
      Blood. 2002 Apr 1;99(7):2331-6. (PMID: 11895764)
      Cell Rep. 2014 Jan 16;6(1):130-40. (PMID: 24388756)
      Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4762-8. (PMID: 25341731)
      Mod Pathol. 2017 May;30(5):745-760. (PMID: 28084335)
      J Mol Diagn. 2019 Mar;21(2):330-342. (PMID: 30590126)
      Blood Cancer J. 2021 May 26;11(5):102. (PMID: 34039950)
      APMIS. 2007 Jul;115(7):869-74. (PMID: 17614857)
      Blood. 2013 May 2;121(18):3666-74. (PMID: 23460611)
      J Biol Chem. 2015 Mar 6;290(10):6361-75. (PMID: 25561738)
      Cancers (Basel). 2021 Feb 19;13(4):. (PMID: 33669719)
      Cancers (Basel). 2022 Feb 25;14(5):. (PMID: 35267506)
      Virology. 2011 Apr 25;413(1):1-11. (PMID: 21353276)
      J Biol Chem. 2007 Jul 13;282(28):20395-406. (PMID: 17500065)
      J Clin Invest. 2006 Mar;116(3):735-42. (PMID: 16498502)
    • Contributed Indexing:
      Keywords: HHV8; HHV8+ DLBCL; MCD; extra-cavitary PEL; microlymphoma; mutations; somatic hypermutation
    • الرقم المعرف:
      0 (Immunoglobulin M)
    • الموضوع:
      Multi-centric Castleman's Disease
    • الموضوع:
      Date Created: 20240413 Date Completed: 20240415 Latest Revision: 20240425
    • الموضوع:
      20240425
    • الرقم المعرف:
      PMC11011749
    • الرقم المعرف:
      10.3390/ijms25073775
    • الرقم المعرف:
      38612584